公开(公告)号：US20220213176A1

公开(公告)日：2022-07-07

申请号：US17702710

申请日：2022-03-23

Applicant: ShanghaiTech University ,  ShOx Science Limited

Inventor： Peixiang Ma ,  Guang Yang ,  Richard A. Lerner ,  Min Qiang ,  Hou Wang

IPC: C07K16/10 ,  A61P31/14

Abstract: The present disclosure provides human antibodies and fragments thereof having binding specificity to the SARS-CoV-2 spike protein's receptor binding domain (RBD). The antibodies and fragments have strong affinity and potent neutralization ability against the SARS-CoV-2 virus and various mutant forms. Also provided are trimeric antibodies which have further enhanced neutralization capabilities. The antibodies and fragments thus may be used for preventing or treating SARS-CoV-2 viral infection or detecting the presence of the virus in a sample.

公开(公告)号：US20230117596A1

公开(公告)日：2023-04-20

申请号：US17746341

申请日：2022-05-17

Applicant: ShOx Science Limited

Inventor： Bevin GANGADHARAN ,  Abhinav KUMAR ,  Raymond A. DWEK ,  Nicole ZITZMANN ,  Mark THURSZ ,  Jeremy Francis Lars COBBOLD

IPC: G01N33/68

Abstract: The invention relates to methods of diagnosing, prognosing, or monitoring or staging the progression of non-alcoholic fatty liver disease (NAFLD) using biomarkers. The invention also relates to a method of scoring to determine the severity of NAFLD, and a method of treating NAFLD.

公开(公告)号：US12130293B2

公开(公告)日：2024-10-29

申请号：US17746341

申请日：2022-05-17

Applicant: ShOx Science Limited

Inventor： Bevin Gangadharan ,  Abhinav Kumar ,  Raymond A. Dwek ,  Nicole Zitzmann ,  Mark Thursz ,  Jeremy Francis Lars Cobbold

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  G01N2333/775 ,  G01N2333/811 ,  G01N2800/085 ,  G01N2800/56

Abstract: The invention relates to methods of diagnosing, prognosing, or monitoring or staging the progression of non-alcoholic fatty liver disease (NAFLD) using biomarkers. The invention also relates to a method of scoring to determine the severity of NAFLD, and a method of treating NAFLD.